4//SEC Filing
LEBEL FRANCOIS 4
Accession 0001209191-22-039063
CIK 0000831547other
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 8:24 PM ET
Size
12.0 KB
Accession
0001209191-22-039063
Insider Transaction Report
Form 4
LEBEL FRANCOIS
Chief Medical Officer
Transactions
- Sale
Common Stock, $0.001 par value
2022-06-22$0.81/sh−6,096$4,913→ 651,457 total - Award
Common Stock, $0.001 par value
2022-06-21+405,040→ 657,553 total - Sale
Common Stock, $0.001 par value
2022-06-23$0.84/sh−6,667$5,594→ 644,790 total - Award
Stock Option (Right to Buy)
2022-06-21+1,488,940→ 1,488,940 totalExercise: $0.63Exp: 2032-01-27→ Common Stock (1,488,940 underlying)
Holdings
- 7,226(indirect: By 401(k))
Common Stock, $0.001 par value
Footnotes (4)
- [F1]The restricted stock unit grant was approved by Spectrum Pharmaceuticals, Inc.'s ("Spectrum") board of directors on January 27, 2022, subject to stockholder approval of the Amended and Restated 2018 Long-Term Incentive Plan (the "Plan") under which the restricted stock unit was granted. Spectrum's stockholders approved the Plan on June 21, 2022.
- [F2]All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer.
- [F3]The option grant was approved by Spectrum's board of directors on January 27, 2022, subject to stockholder approval of the Plan under which the option was granted. Spectrum's stockholders approved the Plan on June 21, 2022.
- [F4]One third of the aggregate amount of option shares shall vest on each of January 27, 2023, 2024 and 2025, respectively.
Documents
Issuer
SPECTRUM PHARMACEUTICALS INC
CIK 0000831547
Entity typeother
Related Parties
1- filerCIK 0001038704
Filing Metadata
- Form type
- 4
- Filed
- Jun 22, 8:00 PM ET
- Accepted
- Jun 23, 8:24 PM ET
- Size
- 12.0 KB